Baldwin Group reports Q3 revenue up 31% to $480.3 million

Baldwin Insurance reported preliminary Q3 2026 revenue of $480.3 million, up 31% year over year, and adjusted EBITDA of $106.9 million, up 47%, while its net loss widened to $81.6 million from $30.2 million. The company had $2.465 billion in total debt and $188.6 million in cash at quarter-end. A previously announced definitive merger agreement would pay shareholders $32.50 per share in cash, with closing expected in Q1 2027 subject to shareholder and regulatory approvals.

Analysis

The key distinction is earnings quality, not headline growth: 31% reported revenue growth alongside 6% organic growth suggests acquired or other non-organic contribution is doing much of the scaling. EBITDA margin expansion is constructive, but the substantially larger GAAP loss means investors should verify the 10-Q bridge—especially interest, amortization, transaction costs, and any noncash items—before treating adjusted EBITDA as durable cash-earning power. This matters less if the cash merger closes, but more if it breaks: debt of $2.465 billion could amplify downside through financing costs and a reset to standalone valuation. The $32.50 offer anchors near-term value, not a guaranteed floor; cash and undrawn revolver capacity are not equivalent to excess cash available to equity holders.

Near term, BWIN is principally a merger-arbitrage and closing-risk instrument rather than a clean operating-growth exposure. Through Q1 2027, shareholder and regulatory approvals and buyer financing certainty are the catalysts; the preliminary, unaudited figures add reporting risk but are unlikely to create much upside beyond the fixed consideration. Over 6–18 months, if the deal closes, the company’s standalone growth and leverage cease to be public-equity catalysts. If it fails, modest organic growth against acquisition-led reported growth and substantial debt could make the break-price downside meaningfully larger than the remaining deal spread. The contrarian point: strong adjusted EBITDA growth may look reassuring, but it does not resolve the gap between adjusted performance and GAAP losses—or establish standalone equity value.

Key Decisions for Investors

• Do not underwrite BWIN as an ordinary earnings-growth long at the offer price. For a merger-arbitrage position, first compare the live share price with $32.50 and calculate annualized spread to expected close; no entry recommendation is possible without that price and a downside estimate if the transaction terminates.
• If the deal spread is attractive after accounting for break risk, keep any position sized to a binary event and monitor shareholder approval, regulatory progress, and evidence of buyer financing. Reassess immediately on a delayed timetable, adverse regulatory development, or amendment/termination of the merger agreement.
• Treat the 10-Q as the next fundamental checkpoint: verify organic growth by segment, acquisition contribution, GAAP-to-adjusted EBITDA reconciliation, cash-flow conversion, debt terms, and revolver availability. A material deterioration in cash generation or guidance would raise break-risk severity; clean reconciliation would support the deal case but does not create uncapped upside.
• Falsification / risk trigger: a credible deal failure would invalidate the $32.50 anchor and expose standalone valuation risk; conversely, completed approvals and closing would end the public-equity thesis. Avoid inferring a specific break price without standalone valuation and comparable-company data.